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Introduction: Pediatric systemic lupus erythematosus (pSLE) patients often initially present with more active and
severe disease than adults, including a higher frequency of lupus nephritis. Specific autoantibodies, including
anti-C1q, anti-DNA and anti-alpha-actinin, have been associated with kidney involvement in SLE, and DNA
antibodies are capable of initiating early-stage lupus nephritis in severe combined immunodeficiency (SCID) mice.
Over 100 different autoantibodies have been described in SLE patients, highlighting the need for comprehensive
autoantibody profiling. Knowledge of the antibodies associated with pSLE and proliferative nephritis will increase
the understanding of SLE pathogenesis, and may aid in monitoring patients for renal flare.
Methods: We used autoantigen microarrays composed of 140 recombinant or purified antigens to compare the
serum autoantibody profiles of new-onset pSLE patients (n = 45) to healthy controls (n = 17). We also compared pSLE
patients with biopsy-confirmed class III or IV proliferative nephritis (n = 23) and without significant renal involvement
(n = 18). We performed ELISA with selected autoantigens to validate the microarray findings. We created a multiple
logistic regression model, based on the ELISA and clinical information, to predict whether a patient had proliferative
nephritis, and used a validation cohort (n = 23) and longitudinal samples (88 patient visits) to test its accuracy.
Results: Fifty autoantibodies were at significantly higher levels in the sera of pSLE patients compared to healthy
controls, including anti-B cell-activating factor (BAFF). High levels of anti-BAFF were associated with active disease.
Thirteen serum autoantibodies were present at significantly higher levels in pSLE patients with proliferative
nephritis than those without, and we confirmed five autoantigens (dsDNA, C1q, collagens IV and X and aggrecan)
by ELISA. Our model, based on ELISA measurements and clinical variables, correctly identified patients with
proliferative nephritis with 91 % accuracy.
Conclusions: Autoantigen microarrays are an ideal platform for identifying autoantibodies associated with both
pSLE and specific clinical manifestations of pSLE. Using multiple regression analysis to integrate autoantibody and
clinical data permits accurate prediction of clinical manifestations with complex etiologies in pSLE.Introduction
Systemic lupus erythematosus (SLE) is a complex, chronic
autoimmune disease with diverse signs and symptoms that
commonly affect multiple organs and tissues. SLE has an
unpredictable course, with periods of flares and remis-
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(RNP), are a defining feature of SLE. Prior to diagnosis
with SLE, patients gradually accumulate new autoanti-
bodies, and have an average of three (from Ro, La, anti-
phospholipid (APL), antinuclear antibody (ANA), dsDNA,
Smith, and RNP) at diagnosis [1]. Many patients likely
have additional autoantibodies, as >100 autoantigens have
been described in SLE [2]. Levels of autoantibodies
fluctuate with disease activity and are associated with spe-
cific organ involvement in SLE [3]. Autoantibodies can
directly cause pathology in SLE, as a human anti-DNAarticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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lupus nephritis (LN) in severe combined immunodefi-
ciency (SCID) mice [4].
Ten to twenty percent of SLE patients have disease on-
set in childhood or adolescence. Pediatric SLE (pSLE)
patients often initially present with more acute and se-
vere disease than adults [5], including a higher frequency
of LN observed at presentation [6, 7]. LN is one of the
primary causes of morbidity and mortality in pSLE [8].
Clinicians regularly evaluate urinary parameters, includ-
ing hematuria, pyuria, cellular casts and proteinuria, to
aid in the diagnosis and monitoring of LN. However,
these metrics have low accuracy, especially in the context
of monitoring for renal flare [9]. Candidate biomarkers for
LN in pSLE include antibodies against dsDNA [3, 10],
complement C3 and C4 levels [10], urine mRNAs [11],
urine chemokines [12, 13], and urine proteins/peptides
[14, 15]. While measurement of anti-dsDNA and comple-
ment C3 and C4 levels are commonly available clinical la-
boratory tests, only 50 % of LN patients display a decrease
in C3 and C4 or increase in anti-dsDNA antibodies
concurrent with a flare [9, 16]. While multiple factors in-
fluence the development of LN, including complement,
autoantibodies, environment, and genetics [17], the major-
ity of these approaches only measure single analytes, and
may not capture the clinical heterogeneity in SLE.
Autoantigen microarrays allow highly multiplexed meas-
urement of serum autoantibodies that recognize purified
or recombinant protein and nucleic acid-containing auto-
antigens. Our group has developed microarrays to measure
autoantibodies targeting known autoantigens [18, 19],
cytokines and chemokines [20], and modified peptides
[21]. This platform enables the characterization of multiple
autoantibodies in parallel, while using microliter amounts
of patient sera. To our knowledge, autoantigen microarrays
have yet to be used to identify autoantibodies associated
with pSLE or predictive of pSLE LN. An advantage of using
highly multiplexed experimental platforms is that they can
be used to identify multianalyte signatures or scores associ-
ated with clinical features of SLE. For example, gene ex-
pression microarrays were used to identify the interferon
(IFN) signature, associated with active and severe forms of
SLE, and protein microarrays were used to establish the
chemokine score, associated with disease activity and pre-
dictive of flares in SLE [22–25].
In-depth knowledge of the diverse profiles of autoanti-
bodies present in the serum of pSLE patients will in-
crease our understanding of SLE, and aid in disease
diagnosis and prognosis. There is significant interest in
identifying autoantibody profiles that are associated with
LN and predictive of renal flares, with a goal to enable
preemptive treatment. In the current study, we utilized
autoantigen microarrays to identify novel serum auto-
antibodies associated with pSLE. This included anti-Bcell-activating factor (BAFF), which we found was asso-
ciated with active disease. We also identified autoanti-
bodies associated with proliferative nephritis in pSLE,
including autoantibodies against aggrecan and collagens
IV and X. Using autoantibody measurements in combin-
ation with clinical information, we developed a nephritis
score that identified patients who have proliferative
nephritis with high accuracy. In the future, a similar
score could be used to enhance the diagnosis and moni-
toring of proliferative nephritis in pSLE patients.
Methods
Patients
SLE patients with presentation prior to age 18 who met
American College of Rheumatology revised criteria for
classification of SLE [26] were recruited at the Pediatric
Rheumatology Clinic at Stanford Children’s Health
and Lucile Packard Children’s Hospital Stanford. Age-
appropriate consent and assent were obtained. Serum
was collected from 70 new-onset patients and age- and
sex-matched healthy control serum was purchased from
Biodesign International Inc. (Saco, ME, USA) (n = 17).
The Stanford University Institutional Review Board ap-
proved this study (IRB protocol number 13952). Patient
demographics and characteristics at time of collection
are available in Table 1. The patients were followed an
average of 4.2 years (range 0–10.7 years). Pathologists
classified patient kidney biopsies according to the Inter-
national Society of Nephrology/Renal Pathology Society
(ISN/RPS) 2003 classification [27]. The patient cohort
was divided into training (n = 41) and test (n = 23) sets
based on the order in which they were collected. The
training set consists of pSLE patients with biopsy-
confirmed class III or IV proliferative nephritis (n = 23),
and patients with no significant evidence of proliferative
nephritis (n = 18). Four patients were suspected to have
nephritis, but were excluded from the training set and
treated as ‘unknown’ because of inconclusive biopsy
(n = 1), or lack of biopsy due to bleeding risk (n = 2) or
cardiac involvement (n = 1). The nephrologist con-
cluded that the first patient’s biopsy was inconclusive
due to the presence of scar tissue, which prevented
classification. We utilized a test set of 23 patients with
(n = 8) biopsy-confirmed class III or IV proliferative
nephritis, or with either biopsy-confirmed class II neph-
ritis or without significant renal involvement (n = 15),
to test accuracy of the prediction model. Two patients
with class V nephritis were assayed alongside the test
set to assess the model’s performance with membranous
nephritis samples. Five pSLE patients from the test set
were selected based on their disease progression for lon-
gitudinal analysis: two who developed biopsy-confirmed
LN, at 351 days (class III) and 1303 days (class IV) after
their initial visit, two age-matched controls who were
Table 1 Patient demographics
Variable Training (n = 41) Test (n = 23) Combined (n = 64a)
Age at diagnosis, mean (range) years 13.9 (7.5–18.1) 13.7 (9.5–18.1) 13.8 (7.5–18.1)
Sampling date, postdiagnosis (range) days 15 (0–62) 5 (0–32) 12 (0–62)
Number (%) females 37 (90) 20 (87) 57 (89)
ANA-positive patients (%) 40 (98) 23 (100) 63 (98)
dsDNA antibody-positive patients (%) 35 (83) 19 (83) 53 (83)
Class III/IV lupus nephritis-biopsy provenb (%) 23 (56) 8 (35) 31 (48)
Mean (range) SLEDAI score 14 (4–30) 14 (4–29) 14 (4–30)
Treatment at sample:
PO steroids (%) 17 (41) 4 (20) 21 (33)
IV steroids (%) 18 (44) 1 (5) 19 (30)
HCQ (%) 18 (44) 8 (40) 26 (41)
Other IS (%) 6 (15) 0 (0) 6 (9)
None 10 (24) 12 (60) 22 (34)
Hispanic (%) 16 (39) 9 (39) 25 (39)
Asian/Pacific Islander (%) 12 (29) 8 (35) 20 (31)
Non-Hispanic Caucasian (%) 10 (24) 5 (22) 15 (23)
Black (%) 2 (5) 1 (4) 3 (5)
ANA antinuclear antibody, SLEDAI systemic lupus erythematosus disease activity index, PO per os, IV intravenous, HCQ hydroxychloroquine, IS immunosuppressive
therapy (cyclophosphamide, mycophenolate, or methotrexate), None no treatment or NSAID alone
aFour new-onset patients who were suspected to have proliferative nephritis, but were not biopsy-confirmed, were not included in the training and test sets, or
these demographics. Similarly, two patients with class V nephritis were not included in the training and test sets, or these demographics
bOne patient who developed class IV nephritis 4 years after her initial visit, and a second patient who developed class V nephritis 5 years after her initial visit,
were considered negative for this analysis
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who had a relatively stable disease course. Anti-dsDNA
and anti-C1q immunoglobulin G (IgG) levels of each sam-
ple were determined by ELISA, and a chart review was
performed to collect all applicable clinical data.
Autoantigen microarrays
As previously described, we used autoantigen microarrays
to identify patient serum autoantibodies [28]. Briefly, 140
recombinant or purified autoantigens were printed on the
surface of 1-pad nitrocellulose FAST microarray slides
(Whatman, GE Healthcare Life Sciences, Piscataway, NJ,
USA), in replicates of six, using a VersArray ChipWriter
Pro arraying robot (Bio-Rad Laboratories, Inc., Hercules,
CA, USA). Silicon quill pins with 75 micron tips and ap-
proximately 120 nL reservoir volume were used (Parallel
Synthesis Technologies, Santa Clara, CA, USA). Autoanti-
gens were diluted in phosphate-buffered saline (PBS) at a
concentration of 200 μg/mL (see Table S2 in Additional
file 1 for a list of autoantigens). Microarrays were probed
with patient serum, diluted 1/200 in phosphate-buffered
saline with Tween 20 (PBST) with 3 % fetal calf serum
(FCS), followed by detection using a Cy5-labeled goat
anti-human IgG (Fcγ specific) secondary antibody (The
Jackson Laboratory, Bar Harbor, ME, USA). Microarray
slides were scanned using a GenePix 4000B MicroarrayScanner (Molecular Devices, Sunnyvale, CA, USA). Fluor-
escent images were analyzed using GenePix Pro 6.0
Acquisition and Analysis Microarray Software (Molecular
Devices). Median fluorescence intensity (MFI) minus
background was determined for each feature. Negative
MFI minus background signals were set to zero. The data
discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus [29] and are accessible
through GEO Series accession number GSE69662 [30].
Enzyme-linked immunosorbent assay (ELISA)
We performed serum autoantibody ELISA with selected
autoantigens to validate the microarray findings. Ninety-
six-well MaxiSorp ELISA plates (Nunclon, Thermo Fisher
Scientific, Waltham, MA, USA) were coated with 2 ug/ml
of the following antigens in PBS: complement C1q (Biode-
sign), histone H1, histones H2A and H4, histone H2B
(Immunovision, Springdale, AR, USA), collagen types IV
and X from human placenta (Sigma-Aldrich, St Louis,
MO, USA), plasmid dsDNA (Diarect, Freiburg, Germany),
aggrecan from bovine articular cartilage (Sigma-Aldrich),
or bovine serum albumin (BSA, Sigma-Aldrich) as a nega-
tive control. Serum samples were diluted between 1/200
and 1/800 in PBS (with 0.05 % Tween-20 + 5 % FCS)
and used to probe duplicate wells. Wells were incubated
with dissociation-enhanced lanthanide fluoroimmunoassay
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Perkin Elmer, Waltham, MA, USA), and a Wallac Victor
model 1420 Multilabel Counter was used to measure time-
resolved fluorescence (Perkin Elmer). The BSA signal of
each serum sample was subtracted from the signal for a
given antigen. The B cell-activating factor (BAFF)
ELISA was performed according to a previously de-
scribed protocol [20].
Statistical analysis
Significance analysis of microarrays (SAM) was used to
identify autoantigens with significantly different reactiv-
ity between pSLE patients and controls, and patients
with and without proliferative nephritis [31]. Calcula-
tions were performed with R 3.0.2 [32] and the samr
package [33]. The following settings were used: number
of permutations = 1000, q-value <0.001, fold change >2.
Heatmaps were generated using the gplots package [34].
Least absolute shrinkage and selection operator (LASSO)
analyses [35] were performed with R 3.0.2 [32] and the
glmnet package [36]. The following settings were used:
family = binomial, alpha = 1, lamba = 1 SE from minimum.
As described, prior to LASSO analysis, ELISA values for
each autoantigen were normalized to the 95th percentile
value [23]. Urinalysis results were converted to binary vari-
ables: urine red blood cell (URBC) or white blood cell
count (WBC) >5 per high-power field (HPF) and urine
protein to creatinine ratio >0.2 were considered abnormal.
In rare instances where a clinical laboratory result was not
available for a specific visit (e.g. contaminated urinalysis),
the result from the closest visit in time was carried back or
forward. If a clinical laboratory result from another visit
was not available, the median value was used. In an effort
to generate a model suitable for monitoring renal activity,
we removed additional variables that are typically only col-
lected at the initial visit prior to performing LASSO, in-
cluding SLE diagnostic criteria, APL, anti-Sm, anti-RNP,
anti-Ro, and anti-La. This did not significantly impact the
performance of the model. The input variables used in the
LASSO analysis are listed in Table S1 in Additional file 1.
Based on the training set data, LASSO was used to fit
linear models in a stepwise progression along a sequence
of values that penalize model complexity (magnitude of
the coefficient vector). Cross-validation was used to esti-
mate the best penalty value, and the coefficients at this
value were used to create the linear equation shown here:
Score ¼ −4:193þ 2:606 C1qð Þ þ 2:924 dsDNAð Þ
þ 0:064 WBCð Þ−0:013 Hgbð Þ
þ 0:001 ALCð Þ−0:016 C4ð Þ−0:012 ESRð Þ
þ 5:698 URBCð Þ
This equation was used to calculate each patient’s
nephritis score. In the equation, anti-C1q and anti-dsDNA represent normalized serum ELISA values, and
the following abbreviations were used: white blood cell
count (WBC), hemoglobin (Hgb), absolute lymphocyte
count (ALC), complement C4 (C4), erythrocyte sedi-
mentation rate (ESR), and abnormal urine red blood
cells (URBC; binary). Coefficients have been rounded to
three decimal places.
For ELISA, Prism 6 software (GraphPad Software, Inc.,
San Diego, CA, USA) was used to perform Mann–
Whitney tests (without adjustment for multiple tests),
comparing reactivity between patients with and without
proliferative nephritis.
Results
Autoantigen microarrays identify multiple antibodies
associated with pediatric SLE
We used serum samples from new-onset pediatric SLE
patients (n = 46) and age-matched healthy controls (n =
17) to probe autoantigen microarrays featuring 140
purified or recombinant autoantigens (Table S2 in
Additional file 1). To identify autoantibodies that are as-
sociated with pSLE, we used significance analysis of mi-
croarrays (SAM) to find significant differences in serum
IgG reactivity between the pSLE patients and healthy con-
trols (Fig. 1). The analysis identified 50 significant autoan-
tigens, all of which had higher reactivity in pSLE patient
serum than in healthy control serum (q-value <0.001, fold
change >2), including known serologic markers for SLE
(e.g. Ro, La, Smith, dsDNA, histones, RNP). In addition to
known markers, our analysis identified candidate autoanti-
gens that, to our knowledge, have not been previously re-
ported in pSLE, including collagen type X, oxoglutarate
dehydrogenase complex E2 (OGDC-E2), Speckled 100
kDa (sp100), PL-12, signal recognition particle 54 kDa
(SRP54) and BAFF.
Unsupervised hierarchical clustering of the microarray
data revealed pSLE patients and healthy controls as-
sorted into multiple distinct groups based on their auto-
antigen reactivity (Fig. 1). Clusters in the phylogenetic
tree are colored to highlight the groups, which predomin-
antly include patients with reactivity to Sm/RNP-related
antigens (red), DNA/histone-related antigens (magenta),
Ro/La (blue), and RiboP (green). Healthy controls and a
small subset of SLE patients had relatively low reactivity
to most antigens (black cluster).
BAFF autoantibodies are associated with active disease in
pediatric SLE
Our group previously identified BAFF autoantibodies in
the sera of adult SLE patients [20], but BAFF autoanti-
bodies have yet to be reported in pSLE. To validate our
microarray finding, we assayed the serum of 45 pSLE pa-
tients and 24 healthy controls by indirect serum ELISA,
using recombinant BAFF as the antigen. Similar to the
Fig. 1 Autoantigen microarrays identify autoantibodies associated with pediatric SLE. Serum samples from 45 new-onset pSLE patients and 17
age-matched healthy controls were used to probe autoantigen microarrays featuring 140 purified or recombinant autoantigens. Cy5-conjugated
anti-human IgG antibodies were used as a secondary reagent, a fluorescent microarray scanner was used to image each microarray, and the
feature MFIs were used to quantify binding. Significance analysis of microarrays (SAM) was used to identify significant differences in IgG reactivity
to the autoantigens between pSLE patients and controls (q-value <0.001, fold change >2). A hierarchically clustered heatmap (complete linkage,
unsupervised) of the significant autoantigens is shown, with pSLE patients indicated on the top bar in purple and healthy controls in green.
Patient clusters are colored red, blue green and magenta in the phylogenetic tree. IgG immunoglobulin G, MFI median fluorescence intensity,
pSLE pediatric systemic lupus erythematosus, SLE systemic lupus erythematosus
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significantly higher levels in the serum of pSLE patients
than healthy controls (28/45 pSLE patients had reactivity
greater than the maximum healthy control; Fig. 2a). Toinvestigate association of BAFF autoantibodies with dis-
ease activity, we divided the pSLE patients into groups
based on their serum reactivity to BAFF and compared
SLE disease activity index (SLEDAI) between groups
Fig. 2 Anti-BAFF is present in a subset of pediatric SLE patients with active disease. a Recombinant BAFF was used to coat 96-well ELISA plates,
and sera from 45 pSLE patients and 24 age-matched healthy controls were used to probe them in triplicate. HRP-conjugated goat anti-human
IgG (heavy and light chain) was used as a secondary reagent. After development with TMB substrate, absorbance was measured at 450 nm,
and each sample is shown as a percentage of the maximum absorbance. b The pSLE patients were divided into groups based on their serum
reactivity to BAFF. The modified SELENA-SLEDAI is shown for the lowest quartile (Low, <5.8), middle two quartiles (Int), and highest quartile
(High, >11.0). Mann–Whitney tests were used to compare reactivity between groups (bars show mean ± SEM). BAFF B cell-activating factor,
ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin G, HRP horseradish peroxidase, pSLE pediatric systemic lupus erythematosus,
SELENA-SLEDAI Safety of Estrogen in Lupus Erythematosus National Assessment-SLE disease activity index, SLE systemic lupus erythematosus,
TMB 3,3′,5,5′-tetramethylbenzidine
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highest quartile had significantly higher SLEDAI than
those in the lowest quartile.
Autoantigen microarrays identify multiple antibodies
associated with proliferative nephritis
To test whether profiling autoantibodies in the serum of
pSLE patients could identify antigen reactivity patterns
that are associated with nephritis, we divided the pSLE
patients into those with biopsy-proven proliferative neph-
ritis within one year of their initial visit (n = 23), and those
with either biopsy-confirmed class II nephritis or no sig-
nificant evidence of proliferative nephritis (n = 18). We
used SAM to identify differences in serum IgG reactivity
between the groups (Fig. 3), and found 13 autoantigens
with significantly higher reactivity in serum from pSLE
patients with proliferative nephritis than those without
(q-value <0.001, fold change >2). Anti-dsDNA [3, 10],
anti-C1q [10, 37, 38], alpha-actinin [39], and fibrinogen
[40, 41] have been previously associated with LN in SLE
patients. Additional autoantigens we identified had not
been reported previously, including collagens IV and X,
aggrecan, and histones H1, H2B and H2A and H4.
ELISA validation of candidate autoantibodies identified by
microarray
We selected eight candidate proliferative nephritis-
associated autoantigens that were identified by micro-
array, and utilized indirect serum ELISA to validate our
findings. The autoantigens were: dsDNA, complement
C1q, collagens IV and X, aggrecan, histone H1, histone
H2B, and histones H2A and H4. Serum from the 42new-onset pSLE patients was assayed for reactivity to
each of the autoantigens, and we found a high level of
agreement between the microarrays and ELISAs. Six of
eight of the autoantigens tested, dsDNA, C1q, collagens
IV and X, aggrecan, and histone H1, had significantly
higher reactivity in patients with biopsy-proven prolifer-
ative nephritis than in those without (Fig. 4). Levels of
anti-BAFF, as measured by ELISA, did not show an asso-
ciation with proliferative nephritis (data not shown).
These findings confirm anti-dsDNA and anti-C1q are
associated with LN in pSLE, identify aggrecan, collagen
IV, and collagen X autoantibodies as novel markers of
LN in pSLE, and validate autoantigen microarray as a
platform for discovery of candidate biomarkers of LN.
Identification of a pediatric SLE proliferative nephritis
predictive signature
To construct a predictive model of proliferative nephritis
for pSLE patients, we created a training set of ELISA
and clinical measurements from the new-onset pSLE pa-
tient samples (n = 41) used in the microarray analysis
and ELISA validation. We decided to utilize our ELISA
results instead of microarray values in order to create a
model that could be determined at centers without the
requirement of highly specialized microarray equipment.
Clinical measurements in the training set included: urin-
alysis, basic clinical information, SLE diagnostic criteria,
and typical SLE laboratory tests (Table S1 in Additional
file 1). We used the least absolute shrinkage and selec-
tion operator (LASSO) on the training set as a variable
selection and linear regression method [35]. LASSO
selected the following variables in the model: ELISA
Fig. 3 Autoantigen microarrays identify multiple autoantibodies associated with proliferative nephritis in pSLE. Serum samples from 41 new-onset
pSLE patients were used to probe autoantigen microarrays featuring 140 purified or recombinant autoantigens. Anti-human IgG antibodies
conjugated with Cy5 were used as a secondary reagent, a fluorescent microarray scanner was used to image each microarray, and the feature
MFIs were used to quantify binding. Significance analysis of microarrays (SAM) was used to identify significant differences in IgG reactivity to the
autoantigens between patients with biopsy-proven class III/IV nephritis and patients without significant evidence of nephritis (q-value <0.06,
fold change >2). A hierarchically clustered heatmap of the significant antigens is shown. Patients with biopsy-proven proliferative nephritis are
indicated on the top bar in red, while patients without nephritis are shown in blue. IgG immunoglobulin G, MFI median fluorescence intensity,
pSLE pediatric systemic lupus erythematosus, PN proliferative nephritis
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and clinical measurements of absolute lymphocyte count
(ALC), white blood cell (WBC) count, blood hemoglobin
(Hgb), erythrocyte sedimentation rate (ESR), comple-
ment C4 levels, and abnormal urine RBC. We used the
predictive model to calculate nephritis scores for each
patient sample, which are shown in Fig. 5a. The model
successfully partitioned the patients according to whether
they did or did not have proliferative nephritis.
To evaluate the performance of the predictive model,
we used a separate test set of 23 new-onset pSLE patient
samples with biopsy-confirmed class III or IV prolifera-
tive nephritis (n = 8), or without significant renal in-
volvement (n = 15), and the nephritis scores obtained
for each patient with the model are shown in Fig. 5a.
The model correctly categorized patients with proliferative
nephritis with an overall accuracy of 91 %. It is important
to note that two patients who had enough clinical evi-
dence of nephritis to undergo kidney biopsy, but were
found to have class II LN, were correctly assigned negative
nephritis scores, highlighting the specificity of the model.
Two patients with class V LN were analyzed in parallel
with the test set to evaluate the model’s performance on
patients with membranous nephritis, and their scores clas-
sified them in the proliferative nephritis group. The model
was also used to calculate nephritis scores for four ‘un-
known’ samples from new-onset pSLE patients who were
suspected to have proliferative nephritis, but were not
confirmed by biopsy.
Longitudinal analysis of pediatric SLE predictive signature
To determine whether our model could be used to
monitor patients for evidence of proliferative nephritis,we selected five pSLE patients from the test set for
longitudinal analysis based on their disease progression.
The patients included two who developed biopsy-
confirmed proliferative nephritis at 351 days (class III)
and 1303 days (class IV) after their initial visit, two age-
matched controls who were biopsied and found to have
class II LN, and a final subject who had a relatively
stable disease course. Samples from 88 patient visits
were assayed, with an average of 92 days between visits.
ELISA was used to determine each serum sample’s anti-
dsDNA and anti-C1q IgG levels, and a chart review was
performed to collect all applicable clinical data (Table S1
in Additional file 1). The LASSO model based on the
training set was used to calculate nephritis scores for
each patient at each time point (Fig. 5b). In the patients
who developed proliferative nephritis, nephritis scores
increased dramatically and were indicative of prolifera-
tive nephritis 43 days (class III) and 71 days (class IV)
before kidney biopsies were performed. In the three pa-
tients without proliferative nephritis, nephritis scores
remained low, indicative of an absence of proliferative
nephritis throughout the time course.
Discussion
In this study, we analyzed a new pSLE cohort using
autoantigen microarrays, and identified serum autoanti-
bodies that are associated with clinical manifestations of
pSLE. We identified BAFF as a novel autoantigen in
pSLE and found that the presence of BAFF autoanti-
bodies was associated with active disease. We found that
autoantibodies to collagen IV, collagen X and aggrecan
were associated with proliferative nephritis in pSLE. Using
autoantibody measurements and clinical information, we
Fig. 4 ELISA validation of candidate autoantigens identified by microarray. Significance analysis of microarrays (SAM) identified 13 autoantigens as
having significantly different IgG reactivity between pSLE patients with and without proliferative nephritis, of which seven were selected for
further validation using indirect serum ELISA. Purified or recombinant forms of the autoantigens shown above were used to coat 96-well ELISA
plates. Serum from 42 pSLE patients was used to probe them in duplicate, and europium-labeled anti-human IgG (Fcγ specific) was used as a
secondary reagent. Time-resolved fluorescent counts for six of the seven selected autoantigens (minus signal from BSA-coated wells) are shown
above. Mann–Whitney tests were used to compare reactivity between groups (bars show mean ± SEM). BSA bovine serum albumin, ELISA
enzyme-linked immunosorbent assay, IgG immunoglobulin G, pSLE pediatric systemic lupus erythematosus
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fying pSLE patients with proliferative nephritis.
This is the first report of a new pSLE cohort, which in-
cludes a repository of >1087 longitudinal serum samples
from 122 pSLE patients, including 71 new-onset pa-
tients. Extensive clinical information was collected at
each patient visit, covering up to 8 years of clinic visits.
An exceptional feature of the cohort is that autoantigenmicroarray analysis has now been performed on >100 of
the patient samples, making in-depth investigation of
the role of autoantibodies in pSLE possible.
To our knowledge, this is the first description of using
autoantigen microarrays to identify autoantibodies asso-
ciated with pSLE or predictive of pSLE LN. Our analysis
comparing serum IgG reactivity between pSLE patients
and healthy controls identified candidate autoantigens
Fig. 5 Identification of a pediatric SLE proliferative nephritis predictive signature. a Least absolute shrinkage and selection operator (LASSO) was
used on a training set of ELISA and clinical measurements from 41 new-onset pSLE patient samples as a variable selection and linear regression
method to construct a predictive model of proliferative nephritis. A separate test set of 23 new-onset pSLE patient samples was used to evaluate
the performance of the model, and the nephritis scores obtained for each patient with the model are shown. Unfilled black circles indicate
patients who were biopsied and found to be class II, and unfilled black triangles indicate class V nephritis patients. The model was also used to
calculate nephritis scores for samples from new-onset pSLE patients who were suspected to have nephritis, but were not confirmed by biopsy
(unknown). b Five pSLE patients from the test set were selected for longitudinal analysis. ELISA was used to determine each serum sample’s
anti-dsDNA and anti-C1q IgG levels, and a chart review was performed to collect all applicable clinical data. The LASSO model based on the
training set was used to calculate nephritis scores for each patient at each time point. Vertical dashed lines indicate when biopsies were
performed, and the horizontal dashed line indicates the nephritis score cutoff. ELISA enzyme-linked immunosorbent assay, IgG immunoglobulin
G, pSLE pediatric systemic lupus erythematosus, SLE systemic lupus erythematosus
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type X, OGDC-E2, sp100, PL-12, SRP54 and BAFF
(Fig. 1). Our group previously showed that BAFF autoanti-
bodies are present in the serum of adult SLE patients, and
that the autoantibodies were capable of blocking stimula-
tion of the BAFF receptor [20]. In agreement with these
findings, we found significantly higher levels of BAFF
autoantibodies in the serum of pSLE patients than in
healthy controls (Fig. 2a). Further, we found that higher
levels of IgG reactivity were significantly associated withelevated SLEDAI scores. This parallels our group’s report
that the presence of BAFF autoantibodies was associated
with activation of the type I IFN pathway in adult SLE pa-
tients [20, 22]. These findings are important in light of the
fact that BAFF is the target of a fully human, recombinant
monoclonal antibody, belimumab, which was recently
approved for the treatment of SLE [42]. Further studies
will be required to determine whether SLE patients with
BAFF autoantibodies respond differently to belimumab,
compared to patients without BAFF autoantibodies.
Haddon et al. Arthritis Research & Therapy  (2015) 17:162 Page 10 of 12Unsupervised hierarchical clustering of the serum auto-
antibodies of pSLE patients and healthy controls revealed
multiple distinct patient clusters (Fig. 1). The clusters cor-
responded to groups in which the predominant autoanti-
body reactivity was to Sm/RNP-related antigens, DNA/
histone-related antigens, Ro/La, or RiboP, or was relatively
low to most antigens. This clustering pattern bears simi-
larities to autoantibody clusters previously identified in
adult SLE [43, 44] and pSLE [10, 45, 46]. We compared
SLEDAI scores and the frequency of proliferative nephritis
between pSLE patients within each cluster. We found the
low reactivity cluster had lower SLEDAI scores, and the
DNA/histone-related antigens cluster had an increased
frequency of nephritis, although neither reached statistical
significance (data not shown). Other groups have observed
a similar association between DNA/histone-related anti-
gen clusters and nephritis or evidence of nephritis [43, 44,
46]. We are currently investigating the association of these
clusters with other clinical parameters, including evidence
of an association between antibodies to mumps and mea-
sles viruses and the DNA/histone cluster.
To identify autoantibodies associated with proliferative
nephritis, we compared the serum IgG reactivity of pSLE
patients with biopsy-proven proliferative nephritis, and
those with either biopsy-confirmed class II nephritis or
no significant evidence of proliferative nephritis (Fig. 3).
Similar to previous reports, we identified an association
between dsDNA [3, 10] and C1q [10, 37, 38] autoanti-
bodies with LN in pSLE (Figs. 3 and 4). Autoantibodies
to dsDNA are used in the diagnosis of SLE, fluctuate
with disease activity, and are associated with kidney in-
volvement in pSLE [3]. A positive correlation has been
observed between glomerulonephritis and C1q autoanti-
bodies in adult SLE [37]. While C1q autoantibodies were
found in pSLE patient serum, the same association with
LN was not observed in one report [47], but a significant
association with LN was observed in more recent studies
[10, 48, 49]. Similar to previous reports, we observed an
association between LN and autoantibodies to alpha-
actinin and fibrinogen [39–41]. Alpha-actinin is an actin-
binding protein and member of the spectrin family of
proteins. A fraction of dsDNA autoantibodies in the sera
of SLE patients also bind alpha-actinin [39]. Presence of
these cross-reactive autoantibodies was associated with a
higher frequency of glomerulonephritis [39]. Patients in
our cohort may also have had cross-reactive autoanti-
bodies, as there was a relatively strong relationship be-
tween serum levels of anti-dsDNA and anti-alpha-actinin
(R2 = 0.594, p <0.001).
In addition to autoantigens known to be associated
with LN, we found multiple autoantigens that have not
been previously associated with proliferative nephritis,
including aggrecan, collagen IV and collagen X (Figs. 3
and 4). Aggrecan is the major proteoglycan in articularcartilage, and contributes to its resilience. Aggrecan auto-
antibodies have been described in SLE, rheumatoid arth-
ritis, systemic sclerosis, Sjögren’s syndrome, and ankylosing
spondylitis [50]. Collagen IV is a structural protein that
forms networks in the glomerular basement membrane.
Autoantibodies to collagen IV have been reported in SLE,
although their relation to LN was not discussed [51]. Auto-
antibodies to collagen IV are more commonly associated
with Goodpasture’s disease, a rare autoimmune disease in
which autoantibodies damage the lung and kidneys.
Collagen X is a homotrimeric short-chain collagen that is
primarily expressed by chondrocytes, and is a structural
component of articular cartilage. It has previously been
described as an autoantigen in type 1 diabetes [52]. Inter-
estingly, we found that autoantibodies to collagen X were
also higher in pSLE patients than in healthy controls
(Fig. 1). We are currently evaluating whether aggrecan and
collagens IV and X are similarly associated with LN in
adult SLE.
Pathogenesis of LN is influenced by multiple pathways
and factors, including complement, autoantibodies, envir-
onment, and genetics [17]. We utilized a stepwise regres-
sion method, called LASSO, to generate a predicative
model of proliferative nephritis based on multiple clinical
and experimental variables (Fig. 5a and Figure S2 in Add-
itional file 1). LASSO constrains the sum of the absolute
values of the regression coefficients, shrinking the coeffi-
cients of redundant or uninformative variables to zero,
resulting in a sparse model. In this way, LASSO models
tend to be simplified, interpretable, and efficient. Our
model correctly categorized 91 % (21/23) of patients in an
independent test set with 100 % sensitivity and 87 % speci-
ficity (Fig. 5a). For comparison with other clinical mea-
sures, see Figures S1 and S3 in Additional file 1. Our
analysis included samples from four new-onset pSLE pa-
tients who were suspected to have nephritis, but were not
confirmed by biopsy due to inconclusive biopsy, bleeding
risk, or heart involvement (Fig. 5a). Our results suggest
that the patient with an inconclusive biopsy may not have
needed cytotoxic therapy.
Current clinical methods perform poorly at monitor-
ing renal progression, and there is a need for new
methods that might allow preemptive management of
renal flare. While our longitudinal study had a small
sample size, we provide evidence that our nephritis score
is predictive of renal flare (Fig. 5b). We found that neph-
ritis scores increased to levels predictive of proliferative
nephritis between 43 and 71 days before biopsy. We se-
lected the controls of our longitudinal analysis carefully,
including two who were suspected to have nephritis
based on clinical measures and observation, but were
found to have class II LN on biopsy. These patients
would be the most difficult to separate from patients
with proliferative nephritis, highlighting the strength of
Haddon et al. Arthritis Research & Therapy  (2015) 17:162 Page 11 of 12our approach. Interestingly, rebound peaks in the pa-
tients’ nephritis scores were observed immediately fol-
lowing biopsy. This appears to be due to the common
clinical practice of titrating back cytotoxic treatment fol-
lowing a flare, and suggests that nephritis scores could
be used to monitor and avoid similar instances of re-
bound inflammation. In the future, this approach could
be used with a larger cohort to create a similar model to
aid clinicians in diagnosing and monitoring proliferative
nephritis in pSLE patients.
Conclusions
Autoantigen microarrays are an ideal experimental plat-
form for identifying novel serum autoantibodies associated
with pSLE and clinical manifestations of pSLE, including
proliferative nephritis. Using statistical methods, such as
LASSO, to integrate data from multiple sources, including
serum autoantibody profiles and clinical information, will
be crucial to understanding the heterogeneity and com-
plexity of SLE and its clinical manifestations. Our ap-
proach of combining serum autoantibody profiles with
clinical information represents a potential avenue to en-
hance care. A similar model developed with a larger mul-
ticenter cohort could be used as a regular test for pSLE
patients, allowing early detection and preemptive treat-
ment of proliferative nephritis, or in monitoring drug re-
sponse in clinical trials.
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